In a report issued on November 14, Mani Foroohar from Leerink Partners maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report). The company's shares closed last Wednesday at $29.76, close to its 52-week low of $28.75. According to TipRanks.com, Foroohar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -10.9% and a 37.2% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Recursion Pharmaceuticals, and Adverum Biotechnologies. Currently, the analyst consensus on Ionis Pharmaceuticals is a Moderate Buy with an average price target of $54.00, representing an 81.2% upside.
https://www.tipranks.com/news/blurbs/ionis-pharmaceuticals-ions-gets-a-hold-rating-from-leerink-partners?utm_source=advfn.com&utm_medium=referral
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Ionis Pharmaceuticals Charts.
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Ionis Pharmaceuticals Charts.